Assessment the effect of Carvedilol in preventing Heart failure in breast cancer patients.

Assessment of Treatment with Carvedilol in Preventing Heart failure in breast cancer patients under treatment with herceptin or anthracyclines.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017042433619N1

Enrollment

Registered

2017-07-05

Start date

2017-06-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group: Carvedilol 6.25 mg tablet, 12.5 mg two times a day, for 3 months or until the time of heart failure symptoms development. Intervention 2: Control group: No Drug.

Treatment - Drugs

Intervention group: Carvedilol 6.25 mg tablet, 12.5 mg two times a day, for 3 months or until the time of heart failure symptoms development.

Control group: No Drug

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: breast cancer patients under treatment with herceptin or antracyclines. Exclusion criteria: EF less than50%; Significant Valvular Heart Disease; GFR<30ml/h/m2; Hepatic Failure; Contraindications for beta blockers; Symptoms of Heart Failure.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Left and Right Ventricule Function. Timepoint: 3 months after treatment. Method of measurement: Speckle Tracking Echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Nourian

Baqiyatallah University of Medical Sciences

S-nourian@razi.tums.ac.ir+98 21 8248 3347

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026